Bank of America Issues Pessimistic Forecast for LENZ Therapeutics (NASDAQ:LENZ) Stock Price

LENZ Therapeutics (NASDAQ:LENZ) had its price target dropped by Bank of America from $35.00 to $29.00 in a note issued to investors on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Bank of America‘s price objective would indicate a potential upside of 224.38% from the company’s current price.

A number of other analysts have also recently commented on LENZ. Wall Street Zen cut LENZ Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. HC Wainwright restated a “buy” rating on shares of LENZ Therapeutics in a research note on Monday, December 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LENZ Therapeutics in a research report on Thursday, January 22nd. Finally, William Blair reiterated an “outperform” rating on shares of LENZ Therapeutics in a research note on Tuesday, March 10th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, LENZ Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $45.60.

LENZ Therapeutics Trading Down 1.4%

NASDAQ:LENZ opened at $8.94 on Wednesday. The company has a market cap of $280.27 million, a PE ratio of -3.18 and a beta of 0.52. The company has a 50 day simple moving average of $13.95 and a two-hundred day simple moving average of $24.30. LENZ Therapeutics has a 12 month low of $8.56 and a 12 month high of $50.40.

LENZ Therapeutics (NASDAQ:LENZ) last released its quarterly earnings results on Tuesday, March 24th. The company reported ($1.16) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.25). The firm had revenue of $1.59 million during the quarter, compared to analysts’ expectations of $3.09 million. Research analysts forecast that LENZ Therapeutics will post -2.18 earnings per share for the current year.

Institutional Investors Weigh In On LENZ Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Quarry LP bought a new position in LENZ Therapeutics in the 3rd quarter worth $27,000. Bfsg LLC bought a new stake in LENZ Therapeutics during the third quarter valued at about $30,000. State of Wyoming purchased a new stake in LENZ Therapeutics in the fourth quarter worth about $30,000. Caitong International Asset Management Co. Ltd purchased a new stake in LENZ Therapeutics in the fourth quarter worth about $32,000. Finally, Osaic Holdings Inc. raised its stake in shares of LENZ Therapeutics by 2,146.2% in the second quarter. Osaic Holdings Inc. now owns 1,168 shares of the company’s stock worth $34,000 after buying an additional 1,116 shares during the period. 54.32% of the stock is currently owned by hedge funds and other institutional investors.

LENZ Therapeutics News Summary

Here are the key news stories impacting LENZ Therapeutics this week:

• Positive Sentiment: Company highlighted a successful LNZ100 launch and positioned the program as a potential blockbuster opportunity — product momentum and commercial potential support longer‑term upside. LENZ Therapeutics Surpasses Expectations with LNZ100 Launch
• Positive Sentiment: Q4/2025 earnings call emphasized a strong cash position and operational updates that may de‑risk near‑term funding concerns. That balance‑sheet strength is supportive for execution and runway. LENZ Therapeutics, Inc. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Citigroup cut its price target substantially from $52 to $26 but kept a “Buy” rating — a meaningful reset in valuation expectations that still implies sizable upside versus current levels. Benzinga
• Neutral Sentiment: Bank of America trimmed its price target to $29 (from $35) while maintaining a “Buy” rating — another analyst recalibration that tempers near‑term price targets but signals continued conviction. LENZ Therapeutics Given New $29.00 Price Target at Bank of America
• Negative Sentiment: HC Wainwright trimmed FY2028 and FY2029 EPS forecasts slightly (FY2028 to $0.62 from $0.65; FY2029 to $1.71 from $1.84) — the analyst kept a Buy rating but the cuts signal moderated profitability expectations out a few years. MarketBeat – HC Wainwright EPS Revisions
• Negative Sentiment: Recent reported Q4 results missed consensus: EPS and revenue were below estimates, and consensus for the current year remains negative — short‑term fundamentals and missed guidance/revenue contributed to the sell‑side caution. LENZ Therapeutics Inc (LENZ) Q4 2025 Earnings Call Highlights

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.